Kazia Therapeutics Limited
Price Action
Technical Summary
STAGE 2 UPTRENDKazia Therapeutics Limited is in a confirmed Stage 2 uptrend, with price holding above all major moving averages and trend structure remaining intact. Relative strength is leading (RS Rating: 92), indicating clear outperformance against the broad market. Earnings growth of 36% provides fundamental context to the price action. Investors should exercise caution due to high volatility (129% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $13.03 | +10.99% | ABOVE |
| 50 SMA | $12.87 | +12.33% | ABOVE |
| 100 SMA | $10.21 | +41.69% | ABOVE |
| 150 SMA | $9.70 | +49.02% | ABOVE |
| 200 SMA | $9.10 | +58.93% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is KZIA in an uptrend right now?
KZIA has a trend score of 4/4 based on Minervini's Stage Analysis. Yes, KZIA is in a Stage 2 uptrend with price above all major moving averages (50, 100, 150, 200 SMA) properly stacked.
Is KZIA overbought or oversold?
KZIA's RSI (14) is 58. The stock is in neutral territory, neither overbought nor oversold.
Is KZIA outperforming the market?
KZIA has a Relative Strength (RS) Rating of 92 out of 99. Yes, KZIA is a market leader, outperforming 92% of all stocks over the past 12 months.
Where is KZIA in its 52-week range?
KZIA is trading at $14.46, which is 83% of its 52-week high ($17.40) and 77% above its 52-week low ($4.86).
How volatile is KZIA?
KZIA has a Beta of 2.14 and 52-week volatility of 129%. It's more volatile than the S&P 500 - expect bigger swings.